Feline Hyperthyroidism: Welfare Considerations and Long-Term Management
Feline hyperthyroidism is the most common endocrine disorder of older cats, with significant welfare implications if untreated. This page reviews clinical presentation, welfare impacts, treatment options, and quality-of-life management.
What Is Feline Hyperthyroidism?
Hyperthyroidism results from excessive production of thyroid hormones (T3 and T4), most commonly due to benign thyroid adenomatous hyperplasia affecting one or both thyroid glands. It predominantly affects cats over 10 years of age, with prevalence increasing to over 10% in cats above 15 years. The condition is progressive and ultimately fatal if untreated. Causes of the epidemic prevalence in domestic cats are debated; proposed factors include dietary influences (iodine-altered diets, BPA in tin can linings), flame retardants, and environmental endocrine disruptors.
Clinical Signs and Welfare Impact
Untreated hyperthyroidism produces significant welfare compromise: weight loss despite ravenous appetite (causing persistent hunger); restlessness, irritability, and hyperactivity disrupting normal behaviour; polydipsia and polyuria; vomiting and diarrhoea; hypertension causing retinal detachment and blindness; hypertrophic cardiomyopathy from chronically elevated heart rate; and in advanced cases, thyroid storm (acute crisis with severe tachycardia and hyperthermia). The combination of metabolic distress and organ damage represents substantial suffering.
Diagnostic Considerations
Diagnosis requires measurement of total T4 levels, ideally combined with free T4 and clinical assessment. Some hyperthyroid cats have normal T4 within the reference range (occult hyperthyroidism), requiring repeat testing or additional diagnostics. Concurrent conditions—chronic kidney disease (CKD) is particularly important—affect treatment decisions because treating hyperthyroidism may unmask pre-existing CKD by reducing GFR. Welfare-focused management requires evaluation of the whole patient, not just thyroid function.
Medical Management: Antithyroid Drugs
Methimazole (and its prodrug carbimazole) inhibit thyroid hormone synthesis. Daily or twice-daily oral dosing is required indefinitely. Side effects (in ~15% of cats) include: anorexia, vomiting, facial pruritus, thrombocytopenia, and hepatopathy. Transdermal methimazole gel (applied to the inner pinna) improves owner compliance but has lower bioavailability. Medical management requires regular monitoring (T4, renal function, haematology) every 3 months. Welfare considerations include pill administration stress and side effect monitoring.
Radioactive Iodine Treatment
I-131 (radioactive iodine) treatment is considered the gold standard: a single subcutaneous injection selectively destroys hyperfunctional thyroid tissue, providing permanent cure in over 95% of cats. The primary welfare concern is obligatory hospitalisation (3–14 days depending on radiation safety regulations) in a specialist facility, which can be distressing for cats. Post-treatment monitoring for hypothyroidism and CKD emergence is required. Overall welfare outcome is excellent: most cats are cured with a single treatment.
Dietary Management: Iodine-Restricted Diet
Iodine-restricted prescription diets (e.g., Hill's y/d) control hyperthyroidism by limiting substrate for thyroid hormone synthesis. They are effective when fed exclusively—a constraint that requires strict dietary control and is not suitable for multi-cat households where diet exclusivity cannot be guaranteed. Welfare considerations include: palatability (some cats refuse the diet), restricted dietary variety, and the requirement for complete diet exclusivity. Monitoring every 3–6 months is required to assess thyroid control.
Concurrent CKD Management
Approximately 35% of cats diagnosed with hyperthyroidism have concurrent CKD unmasked after treatment. Pre-treatment renal biomarkers (creatinine, SDMA, urine specific gravity) allow risk stratification but cannot reliably predict post-treatment CKD severity. Welfare management involves careful titration of thyroid treatment to maintain mild hyperthyroid state in cats with borderline renal function, balancing the welfare costs of hyperthyroidism against renal deterioration. This complex decision-making requires veterinary expertise and owner engagement.
Summary
Feline hyperthyroidism is highly manageable but produces significant welfare compromise if untreated or poorly managed. Welfare-positive care involves prompt diagnosis, appropriate treatment selection based on the individual cat's circumstances, regular monitoring for treatment efficacy and side effects, and integrated management of concurrent conditions, particularly CKD. Excellent quality of life is achievable for most hyperthyroid cats with consistent, evidence-based management.